Patents by Inventor Vivek Rauniyar
Vivek Rauniyar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11779649Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates comprising antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The application also discloses methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: GrantFiled: December 18, 2019Date of Patent: October 10, 2023Assignee: Novartis AGInventors: Matthew Burger, Joseph Anthony D'Alessio, Tony Fleming, Vivek Rauniyar, Eusebio Manchado Robles, Christian Kunz, Markus Waldhuber
-
Publication number: 20200197528Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: December 18, 2019Publication date: June 25, 2020Inventors: Matthew BURGER, Joseph Anthony D'Alessio, Tony FLEMING, Vivek RAUNIYAR, Eusebio Manchado ROBLES
-
Patent number: 10660888Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.Type: GrantFiled: December 5, 2018Date of Patent: May 26, 2020Assignee: NOVARTIS AGInventors: Jeffrey T. Bagdanoff, Yu Ding, Wooseok Han, Zilin Huang, Qun Jiang, Xianming Jin, Xiang Kou, Patrick Lee, Mika Lindvall, Zhongcheng Min, Yue Pan, Sabina Pecchi, Keith Bruce Pfister, Daniel Poon, Vivek Rauniyar, Xiaojing Michael Wang, Qiong Zhang, Jianguang Zhou, Shejin Zhu
-
Publication number: 20190247392Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.Type: ApplicationFiled: December 5, 2018Publication date: August 15, 2019Inventors: Jeffrey T. BAGDANOFF, Yu DING, Wooseok HAN, Zilin HUANG, Qun JIANG, Xianming JIN, Xiang KOU, Patrick LEE, Mika LINDVALL, Zhongcheng MIN, Yue PAN, Sabina PECCHI, Keith Bruce PFISTER, Daniel POON, Vivek RAUNIYAR, Xiaojing Michael WANG, Qiong ZHANG, Jianguang ZHOU, Shejin ZHU
-
Patent number: 10377770Abstract: The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.Type: GrantFiled: December 15, 2016Date of Patent: August 13, 2019Assignee: Novartis AGInventors: Robert John Aversa, Matthew T. Burger, Michael Patrick Dillon, Thomas A. Dineen, Jr., Rajesh Karki, Savithri Ramurthy, Vivek Rauniyar, Richard Robinson, Patrick James Sarver
-
Patent number: 10188649Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.Type: GrantFiled: August 9, 2017Date of Patent: January 29, 2019Assignee: Novartis AGInventors: Jeffrey T. Bagdanoff, Yu Ding, Wooseok Han, Zilin Huang, Qun Jiang, Xianming Jin, Xiang Kou, Patrick Lee, Mika Lindvall, Zhongcheng Min, Yue Pan, Sabina Pecchi, Keith Bruce Pfister, Daniel Poon, Vivek Rauniyar, Xiaojing Michael Wang, Qiong Zhang, Jianguang Zhou, Shejin Zhu
-
Patent number: 10167279Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: September 11, 2015Date of Patent: January 1, 2019Assignee: Novartis AGInventors: Robert John Aversa, Matthew T. Burger, Michael Patrick Dillon, Thomas A. Dineen, Jr., Yan Lou, Gisele A. Nishiguchi, Savithri Ramurthy, Alice C. Rico, Vivek Rauniyar, Martin Sendzik, Sharadha Subramanian, Lina Quattrocchio Setti, Benjamin R. Taft, Huw Rowland Tanner, Lifeng Wan
-
Publication number: 20180362542Abstract: The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.Type: ApplicationFiled: December 14, 2016Publication date: December 20, 2018Inventors: Robert John AVERSA, Matthew T. BURGER, Michael Patrick DILLON, Thomas A. DINEEN, Jr., Rajesh KARKI, Savrithi RAMURTHY, Vivek RAUNIYAR, Richard ROBINSON, Patrick James SARVER
-
Publication number: 20180170917Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: September 11, 2015Publication date: June 21, 2018Inventors: Robert John AVERSA, Matthew T. BURGER, Michael Patrick DILLON, Thomas A. DINEEN, Jr., Yan LOU, Gisele A. NISHIGUCHI, Savithri RAMURTHY, Alice C. RICO, Vivek RAUNIYAR, Martin SENDZIK, Sharadha SUBRAMANIAN, Lina Quattrocchio SETTI, Benjamin R. TAFT, Huw Rowland TANNER, Lifeng WAN
-
Patent number: 9981977Abstract: The discovery of distinct modes of asymmetric catalysis has the potential to rapidly advance chemists' ability to build enantioenriched molecules. As an example, the use of chiral cation salts as phase-transfer catalysts for anionic reagents has enabled a vast set of enantioselective transformations. A largely overlooked analogous mechanism wherein a chiral anionic catalyst brings a cationic species into solution is itself a powerful method. The concept is broadly applicable to a number of different reaction pathways, including to the enantioselective fluorocyclization of olefins, and dearomatization of aromatic systems with a cationic electrophile-transferring (e.g., fluorinating) agent and a chiral phosphate catalyst. The reactions proceed in high yield and stereoselectivity. The compounds and methods of the invention are of particular value, especially considering the scarcity of alternative approaches.Type: GrantFiled: December 26, 2012Date of Patent: May 29, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Vivek Rauniyar, Aaron D. Lackner, Gregory L. Hamilton, F. Dean Toste, Robert J. Phipps, Hunter Shunatona, Natalja Frueh, Yiming Wang, Jeffrey Wu, Jigar Patel, Takashi Honjo
-
Publication number: 20180028532Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.Type: ApplicationFiled: August 9, 2017Publication date: February 1, 2018Applicant: Novartis AGInventors: Jeffrey T. BAGDANOFF, Yu DING, Wooseok HAN, Zilin HUANG, Qun JIANG, Xianming JIN, Xiang KOU, Patrick LEE, Mika LINDVALL, Zhongcheng MIN, Yue PAN, Sabina PECCHI, Keith Bruce PFISTER, Daniel POON, Vivek RAUNIYAR, Xiaojing Michael WANG, Qiong ZHANG, Jianguang ZHOU, Shejin ZHU
-
Patent number: 9763937Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.Type: GrantFiled: December 9, 2015Date of Patent: September 19, 2017Assignee: Novartis AGInventors: Jeffrey T. Bagdanoff, Yu Ding, Wooseok Han, Zilin Huang, Qun Jiang, Xianming Jin, Xiang Kou, Patrick Lee, Mika Lindvall, Zhongcheng Min, Yue Pan, Sabina Pecchi, Keith Bruce Pfister, Daniel Poon, Vivek Rauniyar, Xiaojing Michael Wang, Qiong Zhang, Jianguang Zhou, Shejin Zhu
-
Publication number: 20170182038Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.Type: ApplicationFiled: December 9, 2015Publication date: June 29, 2017Applicant: Novartis AGInventors: Jeffrey T. BAGDANOFF, Yu DING, Wooseok HAN, Zilin HUANG, Qun JIANG, Xianming JIN, Xiang KOU, Patrick LEE, Mika LINDVALL, Zhongcheng MIN, Yue PAN, Sabina PECCHI, Keith Bruce PFISTER, Daniel POON, Vivek RAUNIYAR, Xiaojing Michael WANG, Qiong ZHANG, Jianguang ZHOU, Shejin ZHU
-
Patent number: 9546173Abstract: The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics.Type: GrantFiled: September 17, 2013Date of Patent: January 17, 2017Assignee: Novartis AGInventors: Michael Patrick Dillon, Mika Lindvall, Daniel Poon, Savithri Ramurthy, Vivek Rauniyar, Cynthia Shafer, Sharadha Subramanian, Huw Rowland Tanner
-
Patent number: 9242996Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.Type: GrantFiled: October 29, 2014Date of Patent: January 26, 2016Assignee: Novartis AGInventors: Jeffrey T. Bagdanoff, Yu Ding, Wooseok Han, Zilin Huang, Qun Jiang, Jeff Xianming Jin, Xiang Kou, Patrick Lee, Mika Lindvall, Zhongcheng Min, Yue Pan, Sabina Pecchi, Keith Bruce Pfister, Daniel Poon, Vivek Rauniyar, Xiaojing Michael Wang, Qiong Zhang, Jianguang Zhou, Shejin Zhu
-
Publication number: 20150274733Abstract: The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions.Type: ApplicationFiled: September 17, 2013Publication date: October 1, 2015Applicant: NOVARTIS AGInventors: Michael Patrick DILLON, Mika LINDVALL, Daniel POON, Savithri RAMURTHY, Vivek RAUNIYAR, Cynthia SHAFER, Sharadha SUBRAMANIAN, Huw TANNER
-
Publication number: 20150126490Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.Type: ApplicationFiled: October 29, 2014Publication date: May 7, 2015Applicant: Novartis AGInventors: Jeffrey T. BAGDANOFF, Yu DING, Wooseok HAN, Zilin HUANG, Qun JIANG, Jeff Xianming JIN, Xiang KOU, Patrick LEE, Mika LINDVALL, Zhongcheng MIN, Yue PAN, Sabina PECCHI, Keith Bruce PFISTER, Daniel POON, Vivek RAUNIYAR, Xiaojing Michael WANG, Qiong ZHANG, Jianguang ZHOU, Shejin ZHU
-
Publication number: 20140350253Abstract: The discovery of distinct modes of asymmetric catalysis has the potential to rapidly advance chemists' ability to build enantioenriched molecules. As an example, the use of chiral cation salts as phase-transfer catalysts for anionic reagents has enabled a vast set of enantioselective transformations. A largely overlooked analogous mechanism wherein a chiral anionic catalyst brings a cationic species into solution is itself a powerful method. The concept is broadly applicable to a number of different reaction pathways, including to the enantioselective fluorocyclization of olefins, and dearomatization of aromatic systems with a cationic electrophile-transferring (e.g., fluorinating) agent and a chiral phosphate catalyst. The reactions proceed in high yield and stereoselectivity. The compounds and methods of the invention are of particular value, especially considering the scarcity of alternative approaches.Type: ApplicationFiled: December 26, 2012Publication date: November 27, 2014Applicant: The Regents Of The University Of CaliforniaInventors: Vivek Rauniyar, Aaron D. Lackner, Gregory L. Hamilton, F. Dean Toste, Robert J. Phipps, Hunter Shunatona, Natalja Frueh, Yiming Wang, Jeffrey Wu, Jigar Patel, Takashi Honjo